Calithera Biosciences} stock has undergone multiple analysts rating changes in the recent past. Calithera Biosciences Downgraded by Zacks Investment Research on 10/11/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Buy.
View More Calithera Biosciences (CALA) Downgraded by Zacks Investment Research to Hold
Quarterly, annual earnings. See the latest EPS estimates vs Actual and surprise it caused. Stock Market Daily has their analysis…
View More Reports First Quarter 2020 Results NYSE:BKD, NYSE:ASXC, NASDAQ:CALA, NYSE:MD
Quarterly, annual earnings. See the latest EPS estimates vs Actual and surprise it caused. Stock Market Daily has their analysis…
View More Must-See Earnings Estimates NASDAQ:RMBL, NASDAQ:CALA, NASDAQ:CTIC, NASDAQ:URGN
Earnings results for Calithera Biosciences , Analyst Opinion on Calithera Biosciences , Earnings and Valuation of (NASDAQ:CALA), Stock market Insights & financial analysis, Best stock to invest, Investment Idea,
View More Factors Likely to Have Influenced Earnings Results Calithera Biosciences (NASDAQ:CALA)
Earnings results for Calithera Biosciences , Analyst Opinion on Calithera Biosciences , Earnings and Valuation of (NASDAQ:CALA), Stock market Insights & financial analysis, Best stock to invest, Investment Idea,
View More Earnings results might Drive Its Stock Price Calithera Biosciences (NASDAQ:CALA)Quarterly, annual earnings. See the latest EPS estimates vs Actual and surprise it caused. Stock Market Daily has their analysis…
View More Reports Strong First-Quarter Financial Results NYSE:LOMA, NYSE:KRP, NASDAQ:CALA, NYSE:GPX
